4:46 PM
 | 
Mar 21, 2019
 |  BC Week In Review  |  Company News  |  Sales & Marketing

NICE recommends Darzalex to treat MM, almost two years after European approval

The U.K.'s NICE recommended this month that Janssen Biotech's Darzalex daratumumab be available through the Cancer Drugs Fund as a second-line...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >